U.S. markets closed

Anthera Pharmaceuticals, Inc. (ANTH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0395-0.0015 (-3.66%)
At close: 3:45PM EST
Sign in to post a message.
  • n
    norman
    Anybody still hanging on to this stock?
  • a
    ariel
    *RESULT study reported positive interim futility analyses and completion of dosing, with top line data expected in March 2018
    *Completed private placement for net proceeds of $13.3 million
    *Received net proceeds of $3.1 million from warrant exercises and sale of shares pursuant to an equity purchase agreement
    *Maintained market capitalization requirement for continued listing on the Nasdaq Capital Market
    *Strengthened management team with addition of Patrick Murphy as Senior Vice President, Manufacturing
  • H
    Hyder
    I came in at 0.51 was it an educated decision to come in at that price?
  • p
    pierfranco
    finlly phase 3 trial seems to be positive
  • J
    JR
    In 2011, post split adjusted price hit close to 600. Mid 2015, it hit close to 100. I think at the current price, we have a lot of potential explosive energy if we get positive results from Phase 3 study. I'm holding for that press release, good or bad.
  • c
    chris
    They said it will be released in the coming days. Sounds promising
  • R
    Robin
    Shelf offering in after hours.
  • J
    JR
    This shelf offering can only mean one thing - ANTH is expecting eventual approval and wants the option to raise quick cash. I see today's PR as positive.
  • W
    W
    Double Digit Soon.
  • w
    wow boy
    ONCE WE HIT .60 WILL BECOME ATTRACTIVE TO INVESTORS
  • W
    WJK
    Phase 3 is coming out soon
  • p
    pierfranco
    great week guys! next better
  • J
    JR
    Wouldn't it be interesting if they change the norm and release earnings in the AH market. That would catch a lot of people off guard, particularly shorts. I don't want to leave the computer until I see the PR.
  • t
    tzr
    What goes down must come up! I’m in at .221/ share
  • A
    Anonymous
    I know that this company has a poor track record, but if they ever manage to get approval for sollpura.....the potential market for this drug is about 1.5 to 2 billion $$$. You could be looking at $5 to $10 for ANTH. Not a bad risk to reward if you don't put too much money in it.
  • W
    W
    Sollpura could bring $500M+ revenue in 2/3 years after approval. EXEL is trading at $9B market cap with $600M revenue, ANTH could do the same as well. Buy and Gold here.
  • W
    WJK
    Great buying opportunity
  • Y
    Y
    https://finance.yahoo.com/news/anthera-receives-positive-nasdaq-listing-213000572.html
    HAYWARD, Calif., Jan. 25, 2018-- Anthera Pharmaceuticals, Inc. today announced that on January 24, 2018, Anthera received formal notice that the Nasdaq Hearings Panel granted Anthera’ s request for inclusion ...
    HAYWARD, Calif., Jan. 25, 2018-- Anthera Pharmaceuticals, Inc. today announced that on January 24, 2018, Anthera received formal notice that the Nasdaq Hearings Panel granted Anthera’ s request for inclusion ...
    HAYWARD, Calif., Jan. 25, 2018-- Anthera Pharmaceuticals, Inc. today announced that on January 24, 2018, Anthera received formal notice that the Nasdaq Hearings Panel granted Anthera’ s request for inclusion ...
    finance.yahoo.com
  • D
    DIRK THE DARING BAGHOLDER
    Another loss for the year! No more gambling on biotech stocks for me
  • M
    Martin
    Phase 2 Results are expected sometime this month as you all know. By now the execs have a good understanding on how things are going, right? If things were not going favorable they would be selling shares. No insiders are selling!!